Hai cercato la traduzione di second primary malignancies da Inglese a Sloveno

second primary malignancies
druge primarne malignosti

second primary malignancies (spms)
sekundarne primarne novotvorbe (spn)

cancer (second primary malignancies)
rak (sekundarna primarna malignost)

second primary education development programme(pedpii) 2003–09
drugi programrazvoja primarnegaizobraževanja(pedpii)(2003–2009)

second primary education development programme — pedp ii (2003–09)
drugi program razvoja primarnega izobraževanja (pedp ii) (2003–2009)

an increased incidence of second primary malignancies (spm) has also been observed in patients with newly diagnosed mm receiving lenalidomide.
pri bolnikih z novo diagnosticiranim disemniniranim plazmocitomom, ki so prejemali lenalidomid, so opazili tudi zvišano incidenco drugih primarnih malignosti.

physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of second primary malignancies and institute treatment as indicated.
zdravniki naj pred zdravljenjem in med njim s standardnimi pregledi za rakava obolenja pri bolnikih skrbno ocenjujejo pojav drugih primarnih malignosti in uvedejo zdravljenje, kot je indicirano.

second primary malignancies are known to be associated with lenalidomide exposure which was extended in patients treated with empliciti combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone.
za sekundarne primarne novotvorbe je znano, da so povezane z izpostavljenostjo lenalidomidu, ki pa je bila pri bolnikih, ki so se zdravili z zdravilom empliciti v kombinaciji z lenalidomidom in deksametazonom, daljša kot pri bolniki, ki so se zdravili z lenalidomidom in deksametazonom.

the second primary objective of the study should be the assessment of the compliance with risk minimization recommendations and the controlled access program for patients receiving scenesse.
drugi primarni cilj te študije je ocena upoštevanja priporočil za zmanjševanje tveganja in programa z nadzorovanim dostopom pri bolnikih, ki prejemajo zdravilo scenesse.

there is an increased risk that paediatric patients with prior malignancies may develop second neoplasm when treated with growth hormone, especially if treatment of the primary malignancy involved radiotherapy.
obstaja povečano tveganje, da se pri pediatričnih bolnikih pri uporabi rastnega hormona s predhodnimi malignostmi razvijejo sekundarne novotvorbe, zlasti če so se primarne malignosti zdravile tudi z radioterapijo.

total skeletal uptake of quadramet in studies of 453 patients with a variety of primary malignancies was 65.5 ± 15.5 % of the administered activity.
skupno kopičenje quadrameta v raziskavi na 453 bolnikih z različnimi primarnimi malignomi je znašalo 65,5 ± 15,5 % aplicirane radioaktivnosti.

the mah should distribute in member states where thalidomide celgene is in use a direct healthcare professional communication letter informing healthcare professionals of the risk of second primary malignancies (spm) in patients treated with thalidomide celgene, in accordance with its communication plan.
imetnik dovoljenja za promet z zdravilom mora v državah članicah, kjer se zdravilo thalidomide celgene uporablja, razposlati neposredno obvestilo zdravstvenim delavcem, v katerem zdravstvene delavce obvešča o tveganjih drugih primarnih malignosti pri bolnikih, zdravljenih z zdravilom thalidomide celgene, v skladu z načrtom obveščanja.

deaths due to second primary malignancy included 8 (3.9%) patients in the zevalin arm compared to 3 (1.5%) patients in the control arm.
smrti zaradi druge primarne maligne bolezni so vključevale 8 (3,9 %) bolnikov v kraku z zdravilom zevalin in 3 (1,5 %) bolnikov v kontrolnem kraku.

primary aliphatic saturated or unsaturated alcohols/aldehydes/acids/acetals/esters with a second primary, secondary or tertiary oxygenated functional group including aliphatic lactones.
primarni alifatski nasičeni ali nenasičeni alkoholi/aldehidi/kisline/acetali/estri z drugo primarno, sekundarno ali terciarno oksidirano funkcionalno skupino, vključno z alifatskimi laktoni.

an increase of second primary malignancies (spm) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years).
v kliničnih preskušanjih predhodno zdravljenih bolnikov s plazmocitomom, ki so prejemali lenalidomid /deksametazon, so opazili povečanje drugih primarnih malignosti (spm - second primary malignancies) (3,98 na 100 oseb-let) v primerjavi s kontrolnimi skupinami (1,38 na 100 oseb-let).